RT Journal Article
SR Electronic
T1 Automated Western immunoblotting detection of anti-SARS-CoV-2 serum antibodies
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.26.20238733
DO 10.1101/2020.11.26.20238733
A1 Edouard, S.
A1 Jaafar, R.
A1 Orain, N.
A1 Parola, P.
A1 Colson, P.
A1 La Scola, B.
A1 Fournier, P-E.
A1 Raoult, D.
A1 Drancourt, M.
YR 2020
UL http://medrxiv.org/content/early/2020/11/30/2020.11.26.20238733.abstract
AB ELISA and chemiluminescence serological assays for COVID-19 are currently incorporating only one or two SARS-CoV-2 antigens. We developed an automated Western immunoblotting as a complementary serologic assay for COVID-19. The Jess™ Simple Western system, an automated capillary-based assay was used, incorporating an inactivated SARS-CoV-2 lineage 20a strain as antigen, and IgT detection. In total, 602 sera were tested including 223 from RT-PCR-confirmed COVID-19 patients, 76 from patients diagnosed with seasonal HCoVs and 303 from coronavirus-negative control sera. We also compared this assay with the EUROIMMUN® SARS-CoV-2 IgG ELISA kit. Among 223 sera obtained from RT-PCR-confirmed COVID-19 patients, 180/223 (81%) exhibited reactivity against the nucleocapsid and 70/223 (31%) against the spike protein. Nucleocapsid reactivity was further detected in 9/76 (14%) samples collected from patients diagnosed with seasonal HCoVs and in 15/303 (5%) coronavirus-negative control samples. In the subset of sera collected more than 2 weeks after the onset of symptoms, the sensitivity was 94% and the specificity 93%, the latter value probably reflecting cross-reactivity of SARS-CoV-2 with other coronaviruses. The automated Western immunoblotting presented a substantial agreement (90%) with the compared ELISA (Cohen’s Kappa=0.64). Automated Western immunoblotting may be used as a second line test to monitor exposition of people to HCoVs including SARS-CoV-2.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by ANR-15-CE36-0004-01 and by ANR Investissements d Avenir Mediterranee Infection 10-IAHU-03Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All sera were retrospectively tested and no sample was collected specifically for this study which was approved by our institution s ethics committee under No.2020-024.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data are made available in the manuscript and supplementary files.